Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd announced the issuance of 333,333 ordinary shares without disclosure under the Corporations Act, complying with relevant provisions and confirming no excluded information needs to be disclosed. This move aligns with the company’s focus on enhancing its operational capabilities and market positioning in the medical diagnostics industry, particularly in cancer detection and prevention.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for the early detection of cancers. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global burden of cancer through early detection. Rhythm collaborates with global partners to commercialize and distribute its solutions, including the ColoSTAT® Test-Kit for colorectal cancer and the geneType™ genetic risk assessment platform.
Average Trading Volume: 797,763
Technical Sentiment Signal: Sell
Current Market Cap: A$30.28M
See more data about RHY stock on TipRanks’ Stock Analysis page.